Why IMU is a multi multi bagger, page-5230

It depends. If say the full results of the PD1-Vaxx when released show that more patients have achieved complete response, then the share price will surely rocket up. Especially in view of the interest from Roche. The market will put 2 and 2 together and predict how much that NSCLC market is going to be worth, and then re-rate the company accordingly. After all, if one patient can achieve that, then the possibility of others achieving full recovery is certainly there.

Moreover, even if there is no more full recovery, but rather the disease have either improved or stabilised, that in itself is also a big win for these patients because all of them were already on their last legs. They have tried all existing approved treatment and failed. In fact, most of them should be dead already. So to be able to celebrate another New Year, that is a huge plus.

Personally, I feel the full results of the PD1-Vaxx will be very positive. LC have already mentioned in her last ASX interview that many of these patients are still walking around. So we shall have to wait and see now how well they have recovered. The interest from Roche is the greatest hint to me that all is well after they have done their due diligence. Otherwise, why bother?